XOMA Royalty (XOMA) Common Equity (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Common Equity came in at $92.9 million in Q1 2026, up 43.75% year-on-year from $64.6 million in Q1 2025, and up 10.64% quarter-over-quarter from $83.9 million in Q4 2025.
XOMA Royalty (XOMA) Common Equity (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Common Equity across 17 years of filings, most recently posting $92.9 million for Q1 2026.
- Common Equity for Q1 2026 came in at $92.9 million, up 43.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.9 million (up 43.75% YoY), and the FY2025 annual result was $83.9 million, up 35.6% from the prior year.
- Common Equity came in at $92.9 million for Q1 2026 at XOMA Royalty, up from $83.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $139.9 million in Q1 2022 to a low of $61.9 million in Q4 2024.
- The 5-year median for Common Equity is $87.9 million (2025), against an average of $94.1 million.
- Across the five-year window, Common Equity jumped 71.22% in 2022 and slumped 45.58% in 2024, its largest moves.
- XOMA Royalty's Common Equity stood at $124.0 million in 2022, then plunged by 44.6% to $68.7 million in 2023, then decreased by 9.9% to $61.9 million in 2024, then jumped by 35.6% to $83.9 million in 2025, then increased by 10.64% to $92.9 million in 2026.
- The last three Common Equity figures came in at $92.9 million (Q1 2026), $83.9 million (Q4 2025), and $87.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 14.38 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 13.21 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 92.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.88 Mn |
| Dec 31, 2025 | 83.94 Mn |
| Sep 30, 2025 | 87.94 Mn |
| Jun 30, 2025 | 72.44 Mn |
| Mar 31, 2025 | 64.61 Mn |
| Dec 31, 2024 | 61.90 Mn |
| Sep 30, 2024 | 64.79 Mn |
| Jun 30, 2024 | 79.97 Mn |
| Mar 31, 2024 | 62.32 Mn |
| Dec 31, 2023 | 68.70 Mn |
| Sep 30, 2023 | 105.96 Mn |
| Jun 30, 2023 | 110.12 Mn |
| Mar 31, 2023 | 114.53 Mn |
| Dec 31, 2022 | 124.01 Mn |
| Sep 30, 2022 | 130.33 Mn |
| Jun 30, 2022 | 134.96 Mn |
| Mar 31, 2022 | 139.92 Mn |
| Dec 31, 2021 | 141.88 Mn |
| Sep 30, 2021 | 111.58 Mn |
| Jun 30, 2021 | 116.58 Mn |